Latest News

Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Richmond Pharmacology appoints Sandra Johnson as Director of Commercial Project Management

September 2022

We are delighted to announce that Sandra Johnson will join Richmond Pharmacology as its new Director for Commercial Project Management

View Article

Samarjit Singh promoted to New Director of Clinical Operations

August 2022

Richmond Pharmacology is delighted to announce the promotion of Samarjit Singh into the position of Director of Clinical Operations.

View Article

Transforming clinical trials to accelerate drug development – Keith Berelowitz

August 2022

Dr Keith Berelowitz, Richmond Pharmacology’s Director of Operations, wrote recently for Pharmaceutical Market Europe where he outlined how innovations in the design and delivery of clinical trials are speeding up the discovery of new therapies for the benefit of patients, sponsors and health systems.

View Article

Clinical trials and the patient perspective

May 2022

Successful recruitment and retention of patients - an essential element to delivering clinical studies on time.

View Article

Clinical trials: how taking the pills can pay those bills.

April 2022

The Guardian references Richmond Pharmacology in feature on reimbursement for clinical trial volunteers

View Article

NTLA-2001 demonstrates positive results for Intellia Therapeutics and Regeneron Pharmaceuticals

March 2022

The latest interim data released indicates a promising future for ATTR patients.

View Article

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

March 30, 2026

Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).

Clinical Trials Innovation Programme

10 - 11 February 2026

Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.

View event

Low data variability

Exceptional ECG generation

Experts in cardiac safety

Our specialist services

サービス一覧

News

Stay up to date with the latest activity at Richmond Pharmacology

Richmond Pharmacology appoints Sandra Johnson as Director of Commercial Project Management

Samarjit Singh promoted to New Director of Clinical Operations

Transforming clinical trials to accelerate drug development – Keith Berelowitz

Clinical trials and the patient perspective

Clinical trials: how taking the pills can pay those bills.

NTLA-2001 demonstrates positive results for Intellia Therapeutics and Regeneron Pharmaceuticals

Meet the experts

Careers at Richmond

Our Videos

Latest news

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

Events

Clinical Trials Innovation Programme

About us

Knowledge Base

Connect with us